FDA Platform Technology Designation Explained

The Platform Technology Designation Program is a distinct FDA regulatory pathway that targets manufacturing and chemistry, manufacturing, and controls (CMC) efficiency, not clinical-review speed. Where Fast Track, Breakthrough Therapy, Accelerated Approval, and Priority Review are aimed at getting a product through clinical development and FDA review faster, Platform Technology Designation lets a sponsor formally designate a well-understood, reproducible technology — a delivery vehicle, expression system, vector, or similar component — so that manufacturing and product-quality data generated for one product using that technology can be leveraged for later applications that use the same platform, instead of being regenerated from scratch each time.

What the Platform Technology Designation Program Is

The program was created by the Food and Drug Omnibus Reform Act of 2022 (FDORA), enacted December 29, 2022 as part of the Consolidated Appropriations Act, 2023. FDORA added Section 506K to the Federal Food, Drug, and Cosmetic Act, codified at 21 U.S.C. § 356k. It applies to drugs approved under FD&C Act Section 505 and biological products licensed under Public Health Service Act Section 351, including the drug or biologic constituents of combination products — and it has been used in practice primarily for cell and gene therapy vector platforms.

The statute defines a “platform technology” as a well-understood, reproducible technology — which may take the form of a nucleic acid sequence, molecular structure, mechanism of action, delivery method, device, vector, or a combination of these — that is incorporated in or utilized by a drug or biological product. FDA published draft guidance, Platform Technology Designation Program for Drug Development, in May 2024 to describe eligibility factors, designation benefits, how to leverage data from a designated platform, and how to raise a planned designation request in a milestone meeting (see CASRAI’s FDA meeting types guide for how those meetings work). As of this writing that guidance remains in draft form; FDA has not yet issued a final version.

Eligibility Criteria

Under 21 U.S.C. § 356k(b), FDA may designate a platform technology if all of the following are true:

The platform technology is already incorporated in, or utilized by, a drug approved under FD&C Act Section 505 or a biological product licensed under PHS Act Section 351 — in other words, designation is not available for a platform that has never yet supported an approved or licensed product.
There is preliminary evidence that the platform technology could be incorporated in, or utilized by, more than one drug or biological product without adversely affecting the quality, manufacturing, or safety of those products.
Incorporating the platform technology into other drugs or biological products could bring significant efficiencies to the future development, manufacturing, or FDA review process for products that use it.

FDA’s draft guidance elaborates on these statutory factors: reviewers look for a technology that is genuinely reusable with common structural or functional elements across candidate products (for example, the same viral vector backbone, lipid nanoparticle formulation, or expression system used to deliver different genetic payloads), and for a data package substantial enough to support standardized manufacturing controls across that family of products.

How Designation Speeds Manufacturing and CMC Changes

This is the part of the program that most clearly separates it from FDA’s clinical expedited programs. Once a platform technology is designated, a sponsor filing a subsequent application that incorporates that same platform can reference and leverage manufacturing-related information already reviewed by FDA for an earlier product built on it, including:

Batch stability data generated using the platform;
Manufacturing process parameters and process validation data;
Process-related impurity clearance data; and
Certain nonclinical safety data and prior FDA inspection findings tied to the platform’s manufacture.

In practice, that means a sponsor developing a second or third product on a designated platform does not need to rebuild the entire CMC section of its application from zero — it can reference the platform-level data on file, and reviewers already familiar with the platform’s manufacturing profile can focus review effort on what’s actually new about the product (the payload, indication, or formulation), rather than re-evaluating manufacturing fundamentals that haven’t changed. This directly supports the kind of post-approval manufacturing change — a new expression construct on an established vector, a new formulation using an established delivery system — that would otherwise require an extensive standalone CMC review each time. Data leverage rights under the statute run with the designation: only the sponsor that holds the designation, or a party with a full right of reference to that data, can rely on it in a later submission.

The program does not shorten clinical trial timelines, change the evidentiary bar for efficacy, or grant any of the review-acceleration mechanisms (rolling review, more frequent FDA interaction on clinical questions, eligibility for accelerated approval based on a surrogate endpoint) that come with Fast Track or Breakthrough Therapy designation. It is a manufacturing- and CMC-focused efficiency tool layered on top of, not a replacement for, those clinical designations — and a product can, in principle, hold both a clinical expedited-program designation and a platform technology designation at once if it qualifies for each independently.

How It Differs From Fast Track, Breakthrough Therapy, Accelerated Approval, and Priority Review

CASRAI covers FDA’s four clinical expedited programs in detail in FDA Expedited Programs: Fast Track, Breakthrough Therapy, Accelerated Approval, and Priority Review Compared. The short version of how Platform Technology Designation is different:

What it targets. Fast Track, Breakthrough Therapy, Accelerated Approval, and Priority Review all address how quickly, and on what evidentiary basis, a product can move through clinical development and FDA review. Platform Technology Designation addresses how much manufacturing and CMC data has to be regenerated per product once a shared technology platform is already established and understood.
What qualifies a product. The clinical programs turn on the seriousness of the condition being treated and the strength of the clinical evidence. Platform Technology Designation turns on whether the underlying technology — not the specific indication — is well-understood, reproducible, and reusable across products.
What sponsors get. Clinical designations can mean more frequent FDA meetings on trial design, rolling submission, or approval based on a surrogate endpoint. Platform designation means the ability to reference prior manufacturing data across applications that use the same platform, reducing duplicative CMC review work.
They are not mutually exclusive. A gene therapy product, for example, could hold Breakthrough Therapy designation for its clinical program and also rely on a platform technology designation covering the viral vector it’s delivered with — the two operate on different axes of the same development program.

The Designation Request Process and Timeline

A sponsor requests designation for a platform technology already incorporated in an approved drug or licensed biologic. Under 21 U.S.C. § 356k(d)(1), FDA must determine, not later than 90 calendar days after receiving a complete request, whether the platform technology meets the statutory criteria. FDA’s draft guidance recommends sponsors raise a planned designation request with the review division during an existing milestone meeting (such as an IND-stage Type B meeting) rather than filing cold, so the request can be scoped and discussed before formal submission.

The statute also gives FDA authority to revoke a designation. Under 21 U.S.C. § 356k(d)(4), FDA may revoke a platform technology designation if it determines the technology no longer meets the eligibility criteria, and must provide the sponsor a written explanation. This provision is not merely theoretical — see the designation history below.

Designation History: First Grants, 2023-2025

The statute took effect in 2022 and FDA’s draft implementing guidance followed in May 2024, but the program’s first actual designations were not publicly reported until 2025:

June 2025 — FDA granted its first publicly disclosed platform technology designation, to Sarepta Therapeutics, covering the AAVrh74 adeno-associated virus vector used in its approved gene therapy Elevidys and in an investigational limb-girdle muscular dystrophy gene therapy.
July 2025 — FDA revoked Sarepta’s designation after safety concerns emerged in trials using the AAVrh74 platform, including patient deaths reported in press coverage at the time.
October 2025 — FDA granted a second platform technology designation, to Krystal Biotech, covering its non-replicating herpes simplex virus type 1 (HSV-1) viral vector platform used to deliver its gene therapies.

This history is drawn from trade-press reporting (BioSpace, GeneOnline, PharmaLive, and related coverage) rather than a running public FDA registry of designations, since FDA has not published a consolidated public list of platform technology designations at the time of writing — sponsors and observers have generally learned of designations through company disclosures. Given the program is still new and its guidance is still in draft form, expect both the volume of designations and the specifics of FDA’s review approach to keep evolving; treat any designation count or program-status detail here as current as of mid-2026 and worth re-checking against a fresh search before relying on it for a time-sensitive decision.

Frequently Asked Questions

What counts as a “platform technology” under FDA’s definition?

Under 21 U.S.C. § 356k(h), a platform technology is a well-understood, reproducible technology that may consist of a nucleic acid sequence, molecular structure, mechanism of action, delivery method, device, vector, or a combination of these, and that is incorporated in or utilized by a drug or biological product. In practice, the designations granted so far have both covered viral vector delivery systems used across multiple gene therapy candidates.

Does Platform Technology Designation speed up clinical trials?

No. It does not shorten clinical development timelines, change efficacy evidentiary standards, or provide the trial-design interactions that come with Fast Track or Breakthrough Therapy designation. Its benefit is narrowly on the manufacturing and CMC side — letting later applications built on the same designated platform reference prior manufacturing data rather than resubmitting it.

Can more than one company use the same designated platform technology?

Only the sponsor holding the designation, or a party with a full right of reference to that sponsor’s data, can leverage the designated platform’s data in a subsequent application. Designation itself does not transfer rights to a competitor’s use of a similar underlying technology.

Can FDA revoke a platform technology designation?

Yes. Under 21 U.S.C. § 356k(d)(4), FDA can revoke a designation if it determines the platform technology no longer meets the eligibility criteria, providing the sponsor a written explanation. FDA exercised this authority in July 2025, revoking Sarepta Therapeutics’ designation for its AAVrh74 vector platform after safety concerns arose.

Has FDA finalized its Platform Technology Designation Program guidance?

As of this writing, no. FDA issued draft guidance in May 2024 and it had not been finalized as of the most recent reporting reviewed for this page. Sponsors should check FDA’s guidance document database directly for the current status before relying on procedural detail beyond the statute itself.

How is this different from Priority Review or Accelerated Approval?

Priority Review shortens FDA’s review clock for a marketing application, and Accelerated Approval allows approval based on a surrogate endpoint reasonably likely to predict clinical benefit — both are clinical-review mechanisms. Platform Technology Designation instead reduces duplicative manufacturing and CMC review burden across products sharing a common, already-vetted technology. See CASRAI’s FDA Expedited Programs guide for a full comparison of the four clinical programs.

FDA Platform Technology Designation Program: Eligibility and How It Speeds Manufacturing Changes